Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone for solid tumor therapies
APVO•Patent filing expands Aptevo’s solid-tumor platform
Aptevo Therapeutics filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone aimed at solid tumors.
- Platform design supports multiple development paths from one targeting architecture, including radiopharmaceutical candidates or T-cell engager constructs.
- Strategy targets tumor localization via Nectin-4 while engaging PD-L1 to counter immune suppression, seeking better selectivity than single-target approaches.
- Backbone extends the company’s ADAPTIR and ADAPTIR-FLEX platforms, positioning the pipeline for additional payloads or immune-modulating functions.
- Filing strengthens intellectual property coverage, supporting partnering discussions and a broader solid-tumor pipeline build-out.
